Employees protest against shutting down of GSK facility in Bangladesh
pharmafile | July 24, 2018 | News story | Manufacturing and Production | Bangladesh, GSK, manufacturing, protest, union
Employees of the British multinational GlaxoSmithKline (GSK) have led a protest against the shutting down of manufacturing facilities in Bangladesh.
The employees, who have organised under the banner of GlaxoSmithKline Employees’ Union, alleged that a self-seeking group has been conspiring to shut down production in the country, according to United News of Bangladesh.
The General Secretary of the Union, Mr Azam, alleged in a press conference at the Jatiya Press Club, that following the recent meeting of the company’s directors, the process of shutting down production in Bangladesh had begun, as the levels of production and marketing undertaken in the densely populated South Asian nation, had started to be reduced.
Azam stated that: “Although the employees are receiving salaries and other benefits, the company had decreased its production after Eid-ul-Fitr and now completely stop its production from July 22. We are suspecting that the authority will come up with an official declaration to shut down the company on July 26.” He added that no raw materials had been bought after the month of June.
The General Secretary further noted that the company had earned revenue of 10 million Bangladeshi Taka (equivalent to approximately £90,000) between 2013 and 2017. The Bangladeshi government had earned a sizeable portion of this due to the fact that they are an 18% stakeholder in the company.
However Alhajj Sarker, the advisor of the employee’s union urged the government to intervene on the issue as the shutting down of manufacturing could leave hundreds of workers jobless.
Louis Goss
Related Content
Ardena announces €20m expansion following first GMP approval
Ardena has announced that it has received Good Manufacturing Practice (GMP) approval from the Dutch …
GSK shares results from phase 3 trial for gonorrhoea treatment
GSK has announced positive results from its phase 3 EAGLE-1 trial for gepotidacin, a potential …
GSK’s meningococcal vaccine candidate accepted for FDA review
GSK has announced that the US Food and Drug Administration (FDA) has accepted for review …
